149 related articles for article (PubMed ID: 38594687)
21. NGS-analysis to the rescue: dual checkpoint inhibition in metastatic osteosarcoma - a case report and review of the literature.
Nuytemans L; Sys G; Creytens D; Lapeire L
Acta Clin Belg; 2021 Apr; 76(2):162-167. PubMed ID: 31635553
[No Abstract] [Full Text] [Related]
22. A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC.
Lisberg A; Cummings A; Goldman JW; Bornazyan K; Reese N; Wang T; Coluzzi P; Ledezma B; Mendenhall M; Hunt J; Wolf B; Jones B; Madrigal J; Horton J; Spiegel M; Carroll J; Gukasyan J; Williams T; Sauer L; Wells C; Hardy A; Linares P; Lim C; Ma L; Adame C; Garon EB
J Thorac Oncol; 2018 Aug; 13(8):1138-1145. PubMed ID: 29874546
[TBL] [Abstract][Full Text] [Related]
23. Impact of EGFR-TKIs combined with PD-L1 antibody on the lung tissue of EGFR-driven tumor-bearing mice.
Jia Y; Zhao S; Jiang T; Li X; Zhao C; Liu Y; Han R; Qiao M; Liu S; Su C; Ren S; Zhou C
Lung Cancer; 2019 Nov; 137():85-93. PubMed ID: 31563735
[TBL] [Abstract][Full Text] [Related]
24. PD-1, PD-L1, NY-ESO-1, and MAGE-A4 expression in cutaneous angiosarcoma: A case report.
Hashimoto K; Nishimura S; Shinyashiki Y; Ito T; Tanaka H; Ohtani K; Kakinoki R; Akagi M
Medicine (Baltimore); 2022 Jul; 101(28):e29621. PubMed ID: 35839046
[TBL] [Abstract][Full Text] [Related]
25. Hair Repigmentation During Immunotherapy Treatment With an Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Agent for Lung Cancer.
Rivera N; Boada A; Bielsa MI; Fernández-Figueras MT; Carcereny E; Moran MT; Ferrándiz C
JAMA Dermatol; 2017 Nov; 153(11):1162-1165. PubMed ID: 28700789
[TBL] [Abstract][Full Text] [Related]
26. [Immunotherapy with PD-1 and PD-L1 inhibitors for prostate cancer].
Huang L; He J
Zhonghua Nan Ke Xue; 2020 Nov; 26(10):944-948. PubMed ID: 33382229
[TBL] [Abstract][Full Text] [Related]
27. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
28. Analysis of PD-1, PD-L1, and T-cell infiltration in angiosarcoma pathogenetic subgroups.
Tomassen T; Weidema ME; Hillebrandt-Roeffen MHS; van der Horst C; ; Desar IME; Flucke UE; Versleijen-Jonkers YMH
Immunol Res; 2022 Apr; 70(2):256-268. PubMed ID: 35043369
[TBL] [Abstract][Full Text] [Related]
29. Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study.
Boothman AM; Scott M; Ratcliffe M; Whiteley J; Dennis PA; Wadsworth C; Sharpe A; Rizvi NA; Garassino MC; Walker J
J Thorac Oncol; 2019 Aug; 14(8):1390-1399. PubMed ID: 31063864
[TBL] [Abstract][Full Text] [Related]
30. Hyperprogression after anti-programmed cell death ligand-1 therapy in a patient with recurrent metastatic urothelial bladder carcinoma following first-line cisplatin-based chemotherapy: a case report.
Mao S; Zhang J; Guo Y; Zhang Z; Wu Y; Zhang W; Wang L; Geng J; Yan Y; Yao X
Drug Des Devel Ther; 2019; 13():291-300. PubMed ID: 30666091
[TBL] [Abstract][Full Text] [Related]
31. Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis from a clear cell renal cell carcinoma appearing after robotic-assisted partial nephrectomy progressed after ICI therapy, while synchronous PD-L1-positive primary lung squamous cell carcinoma responded very well to ICI therapy: a case report.
Urushibara M; Ishizaka K; Matsutani N; Takahashi M; Nagata M; Okumura T; Matsumoto Y; Tatsuoka S; Nenohi T; Amemiya T; Shimizu Y; Shirakawa T; Kato D
World J Surg Oncol; 2023 Feb; 21(1):37. PubMed ID: 36747242
[TBL] [Abstract][Full Text] [Related]
32. Pulmonary large cell carcinoma, highly positive for PD-L1, shows marked response to pembrolizumab: A case report.
Okabe N; Mine H; Takagi H; Watanabe M; Muto S; Matsumura Y; Shio Y; Suzuki H
Thorac Cancer; 2021 Apr; 12(7):1141-1144. PubMed ID: 33605014
[TBL] [Abstract][Full Text] [Related]
33. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
34. An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
Lin PL; Wu TC; Wu DW; Wang L; Chen CY; Lee H
Eur J Cancer; 2017 Nov; 85():95-105. PubMed ID: 28892778
[TBL] [Abstract][Full Text] [Related]
35. Tumor immune microenvironment of cutaneous angiosarcoma with cancer testis antigens and the formation of tertiary lymphoid structures.
Magara T; Nakamura M; Nojiri Y; Yoshimitsu M; Kano S; Kato H; Morita A
Front Oncol; 2023; 13():1106434. PubMed ID: 37081973
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of programmed death-1 and programmed death-ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma.
Mikami S; Mizuno R; Kondo T; Shinohara N; Nonomura N; Ozono S; Eto M; Tatsugami K; Takayama T; Matsuyama H; Kishida T; Oya M;
Cancer Sci; 2019 Jun; 110(6):1820-1828. PubMed ID: 30972888
[TBL] [Abstract][Full Text] [Related]
37. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
38. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P
Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737
[TBL] [Abstract][Full Text] [Related]
39. Detailed characterization of PD-1/PD-L1 and CTLA4 expression and tumor-infiltrating lymphocytes in yolk sac tumors.
Zhang D; Xu H; Zhao C; Qin L; Wei R; Xi L; Li F
Hum Immunol; 2023 Oct; 84(10):534-542. PubMed ID: 37453913
[TBL] [Abstract][Full Text] [Related]
40. The predictive and prognostic effects of PD-L1 expression on TKI treatment and survival of EGFR-mutant NSCLC: A meta-analysis.
Lan B; Wang Y; Wu J; Wang K; Wang P
Medicine (Baltimore); 2021 Aug; 100(34):e27038. PubMed ID: 34449486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
